ReviewJournal of oral biology and craniofacial research
Molecular effects of areca nut-derived compounds on human oral cancer cells: a systematic review of in vitro evidence.
Review in Journal of oral biology and craniofacial research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Areca nut chewing is a major risk factor for oral potentially malignant disorders (OPMD) and oral squamous cell carcinoma (OSCC), yet the molecular mechanisms underlying its carcinogenic effects remain incompletely integrated. This systematic review aimed to synthesize in vitro evidence on the molecular effects of areca nut extract and areca nut-derived alkaloids in human oral cancer cells. Methods: This systematic review followed PRISMA 2020. PubMed, ScienceDirect, and Scopus were searched from inception to the final search date. Eligible studies used human oral squamous cell carcinoma cell lines or primary oral cancer cells exposed to areca nut extract or related compounds. Outcomes involving inflammation, proliferation, oxidative stress, oncogenic signaling, and tumor-suppressor regulation were qualitatively synthesized because of methodological heterogeneity. Results: Twenty studies met the inclusion criteria. Areca nut-derived compounds were associated with increased pro-inflammatory mediators, including IL-1β, IL-6, IL-8, COX-2, and PGE2. They also altered cell proliferation and cell-cycle control, with increased proliferative markers and suppression of key checkpoint regulators. Oxidative stress was characterized by elevated intracellular and mitochondrial reactive oxygen species, oxidative DNA damage, lipid peroxidation, and impaired antioxidant defenses. Oncogenic and stress-responsive pathways, including NOTCH1, Akt, and Nrf2/HO-1, were activated, whereas p53, p27, SIRT1, and AP-1 transcription factors were downregulated. Findings for p21 were contradictory across studies. Conclusions: In vitro evidence indicates that areca nut constituents induce coordinated inflammatory, proliferative, oxidative, and signaling alterations that support their carcinogenic role in human oral cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.